PAK6

PAK6 (p21-activated kinase 6) is a serine/threonine kinase belonging to the group II PAK family and functions as a downstream effector within Rho GTPase-associated signaling networks that regulate transcription, cytoskeletal organization, cell motility, and cellular behavior^[1][2]. PAK6 was originally identified as an androgen receptor (AR)-interacting kinase, and mechanistically it modulates AR-dependent signaling through direct interaction, phosphorylation, and repression of AR transcriptional activity, establishing a functional link between kinase signaling and steroid hormone responses^[3][4]. In addition to AR-associated regulation, PAK6 participates in signaling pathways that influence cell adhesion dynamics and cellular morphology, supporting its role in coordinating cytoskeletal remodeling and migratory behavior^[1][5]. Disease studies have connected altered PAK6 expression or activity with prostate cancer, hepatocellular carcinoma, and other malignancies, where PAK6-dependent signaling has been implicated in tumor progression, survival, therapeutic response, or regulation of tumorigenic pathways^[6][7]. Compared with the closely related group II isoforms PAK4 and PAK5, PAK6 shares highly similar substrate-recognition characteristics yet displays distinctive biological functions through its established involvement in androgen receptor signaling and tissue-specific physiological phenotypes^[2][3]. For experimental applications, structural and biochemical studies have demonstrated that PAK6 activity can be inhibited by ATP-competitive compounds including PF-3758309 and sunitinib, providing useful pharmacological tools for investigating type II PAK signaling and kinase-dependent cellular mechanisms^[2].